SCHEMBL4191273

SCHEMBL4191273

COc1ccc(S(=O)(=O)N(C)CCN(C2CC2)S(=O)(=O)c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ HIF1A Q16665 6/20 0.50
▸ EPAS1 Q99814 5/20 0.50
▸ PDE4D Q08499 4/20 0.50
▸ EP300 Q09472 1/20 0.50
▸ MAPK1 P28482 1/20 0.49
▸ PDE4A P27815 2/20 0.47
▸ PDE4B Q07343 2/20 0.47
▸ PDE4C Q08493 2/20 0.47
▸ SIGMAR1 Q99720 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ ADRA1D P25100 1/20 0.46
▸ ADRA1A P35348 1/20 0.46
▸ ADRA1B P35368 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176914 0.86 PDE4D (0.61) TSHRHTTSMN1; SMN2PDE4DMAPK1
SCHEMBL4187429 0.85 TSHR (0.56) TSHRHTTSMN1; SMN2TDP1HIF1A
SCHEMBL4176989 0.85 TSHR (0.50) TSHRHTTSMN1; SMN2TDP1HIF1A
SCHEMBL4184689 0.81 KMT2A (0.55) TSHRHTTSMN1; SMN2TDP1HIF1A
SCHEMBL4194071 0.80 PDE4D (0.58) TSHRHTTSMN1; SMN2PDE4DMAPK1
SCHEMBL7205749 0.79 PDE4D (0.57) TSHRHTTSMN1; SMN2PDE4DMAPK1
SCHEMBL4190701 0.79 PDE4D (0.54) TSHRHTTSMN1; SMN2PDE4DMAPK1
SCHEMBL4187978 0.79 PDE4D (0.54) TSHRHTTSMN1; SMN2PDE4DMAPK1
SCHEMBL7204075 0.77 PDE4D (0.55) TSHRHTTHIF1AEPAS1PDE4D
SCHEMBL4184591 0.76 PDE4D (0.52) TSHRHTTSMN1; SMN2PDE4DMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 — — US disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A TSHR 576/4885HTT 935/4885SMN1; SMN2 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback